20-Year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients

Transplantation

Volumn 86, Issue 12, 2008, Pages 1732-1737

  Cantarovich, Marcelo ^a,f   Durrbach, Antoine ^b,c   Hiesse, Christian ^d   Ladouceur, Martin ^e   Benoit, Gerard ^b   Charpentier, Bernard ^b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b BICÊTRE HOSPITAL   (France)

^c INSERM   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e MCGILL UNIVERSITY   (Canada)

^f ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Antilymphocyte globulin; Azathioprine; Cyclosporine; Induction therapy; Renal transplant patients

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; LYMPHOGLOBULINE; METHYLPREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADD ON THERAPY; ANTIGEN DETECTION; ARTICLE; BOWEN DISEASE; CANCER INCIDENCE; CAUSE OF DEATH; CLINICAL TRIAL; COLD ISCHEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RATE; KAPOSI SARCOMA; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER ADENOMA; LIVER CARCINOMA; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOMA; SKIN CANCER; SURGICAL MORTALITY; THYMOMA; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME; DRUG EFFECT; GRAFT REJECTION; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; SURVIVAL; TIME; VIROLOGY;

ANTILYMPHOCYTE SERUM; AZATHIOPRINE; COMBINED MODALITY THERAPY; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PREDNISONE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 58849156485     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318190659d     Document Type: Article

References (46)

1. Traeger J, Perrin J, Fries D, et al. [Use in man of an anti-lymphocyte globulin: Clinical results in renal transplantation]. Lyon Med 1968; 219: 307.
2. Kerman RH, FloydM, Van Buren CT,et al. Improved allograft survival of strong immune responder-high risk recipients with adjuvant anti-thymocyte globulin therapy. Transplantation 1980; 30: 450.
3. Novick AC, Braun WE, Steinmuller D, et al. A controlled randomized double-blind study of antilymphoblast globulin in cadaver renal transplantation. Transplantation 1983; 35: 175.
4. Fries D, Hiesse C, Charpentier B, et al. Optimal results in cadaveric renal transplantation with low-dose cyclosporine and steroids combined with prophylactic anti-lymphocyte globulin. Transplant Proc 1988; 20(5 suppl 6): 23.
5. Cho SI, Bradley JW, Monaco AP, et al. Comparison of kidney transplant survival between patients treated with cyclosporine and those treated with azathioprine and antithymocyte globulin. Am J Surg 1984; 147: 518.
6. Najarian JS, Fryd DS, Strand M, et al. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg 1985; 201: 142.
7. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
8. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduc-tion in renal transplant recipients with tacrolimus-based immunosup-pression. Transplantation 2001; 72: 1050.
9. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123: 18.
10. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoprolifera-tive disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76: 984.
11. Opelz G, Döhler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 153.
12. Kauffman HM, Cherikh WS, McBride MA, et al. Post-transplant de novo malignancies in renal transplant recipients: The past and present. Transpl Int 2006; 19: 607.
13. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769.
14. Gill JS, Johnston O, Rose CL, et al. Are there any benefits to using depleting antibodies in low risk kidney transplant recipients? Am J Transplant 2008; 8(suppl 2): 215.
15. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs. cadaveric renal transplant recipients. JAMA 1993; 270: 1339.
16. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
17. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
18. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
19. Kootte AM, Lensen LM, van Bockel JH, et al. High- and low-dose regimens of cyclosporin in renal transplantation: Immunosuppressive efficacy and side-effects. Nephrol Dial Transplant 1988; 3: 666.
20. Vincenti F, Laskow DA, Neylan JF, et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 1576.
21. Halloran P, Mathew T, Tomlanovich S, etal. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39.
22. Ekberg H, Tedesco-Silva H, Demirbas, et al. Reduced exposure to cal-cineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
23. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy inrenal-transplant recipients. N Engl J Med 2002; 347: 488.
24. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
25. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405.
26. Nankivell B, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
27. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. Am J Transplant 2007; 7: 2538.
28. Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol 2000; 20: 126.
29. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006; 81: 643.
30. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2006; 16: 3015.
31. Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 2006; 16: 148.
32. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
33. Metcalfe MS, Jain S, Waller JR, et al. A randomized trial of mycophe-nolate mofetil versus azathioprine as calcineurin inhibitor sparing agents in the treatment of chronic allograft nephropathy. Transplant Proc 2002; 34: 1812.
34. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755.
35. Tang SC, Chan KW, Tang CS, et al. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft ne-phropathy. Nephrol Dial Transplant 2006; 21: 3243.
36. Jain S, Metcalfe M, White SA, et al. Chronic allograft nephropathy: A prospective randomised trial of cyclosporin reduction with or without mycophenolate mofetil. Transplant Proc 2001; 33: 2165.
37. McGrath JS, Shehata M. Chronic allograft nephropathy: Prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. Transplant Proc 2001; 33: 2193.
38. Meier M, Nitschke M, Weidtmann B, et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to ta-crolimus: A randomized controlled trial. Transplantation 2006; 81: 1035.
39. Stoves J, Newstead CG, Baczkowski AJ, et al. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19: 2113.
40. Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft ne-phropathy. Transplantation 2003; 75: 772.
41. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
42. Montagnino G, Tarantino A, Segoloni GP. Long-term results of a randomized study comparing three immunosuppressive schedules with cyclosporine in cadaveric kidney transplantation. J Am Soc Nephrol 2001; 12: 2163.
43. Beaudreuil S, Durrbach A, Noury J, et al. Long-term results (10 years) of a prospective trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therapy in kidney transplantation. Transpl Int 2006; 19: 814.
44. Rao KV, Andersen RC. Long-term results and complications in renal transplant recipients. Observations in the second decade. Transplantation 1988; 45: 45.
45. Toussaint C, Kinnaert P, Vereerstraeten P. Late mortality and morbidity five to eighteen years after kidney transplantation. Transplantation 1988; 45: 554.
46. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103.